The global HER2-positive gastric cancer market is on a promising growth trajectory, with a current valuation of USD 1,261.8 million in 2023. According to the latest market analysis, this sector is expected to expand at a compound annual growth rate (CAGR) of 3.5% over the next decade. By 2033, the market is projected to reach approximately USD 1,779.8 million.
This positive outlook is driven by significant advancements in healthcare technology and an increasing focus on targeted therapies. The development of innovative treatment options and improved diagnostic tools are expected to contribute to the market’s expansion.
This growth is largely driven by ongoing technological advancements in the healthcare sector, which are enhancing treatment options and improving patient outcomes for those diagnosed with HER2-positive gastric cancer. As research and development in targeted therapies continue to advance, the market is poised for sustained growth over the next decade.
The anticipated expansion reflects the critical importance of innovation in the treatment of gastric cancer, particularly for patients with HER2-positive tumors, who require specialized and effective therapeutic approaches. The market’s growth underscores the healthcare industry’s commitment to improving cancer care and addressing the needs of patients worldwide.
For instance, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers. Additionally, the increasing number of special designations for drugs in the pipeline is also expected to fuel the growth of the market.
North America dominates the HER 2 positive gastric cancer market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.
Key Takeaways from the Market Study
- As of 2023, the HER2 positive gastric cancer market was valued at US$ 1261.8 Million
- From 2023 to 2033, the HER2 positive gastric cancer industry is poised to grow at an 3.5% CAGR
- By 2033, the HER2 positive gastric cancer market is slated to reach a valuation of US$ 1779.8Million
- Based on therapy, the targeted therapy segment dominated the global market in 2023 with a revenue share of over 55.4%.
- China is poised to yield a CAGR of 3.2% with respect HER2 positive gastric cancer in 2033
“Technological advancement in healthcare and increase in the prevalence of gastric cancer is expected to radically transform the HER 2 positive gastric cancer market in the coming years,” comments an analyst at FMI.
Competitive Landscape
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
- Hutchison Medipharma
- LintonPharm
- Shanghai Henlius Biotech
- Sanofi
- Pfizer
- Novartis AG
Manufacturers and players functional in the global HER 2 positive gastric cancer market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.
- In September 2022 -Shanghai Henlius Biotech, Inc announced a phase 1 clinical trial of the company’s HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanised monoclonal antibody(mAb) injection, has been completed in patients with HER2 overexpressing advanced solid tumours. The results of this study demonstrated the good safety and tolerability of HLX22.
- In January 2022 — LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that it has completed the enrollment of stage 1 of the global phase III trial (clinicaltrials.gov: NCT04222114). This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis (GCPC).
A Old Full Report Analysis Click Here
Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey
HER2 Positive Gastric Cancer Market by Therapy:
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Targeted Therapy
HER2 Positive Gastric Cancer Market by Stage:
- Stage I
- Stage II
- Stage III
- Stage IV
HER2 Positive Gastric Cancer Market by End-User:
- Ambulatory surgery centres,
- Hospitals and Specialty clinics
- Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube